ArriVent BioPharma Reports Third Quarter GAAP EPS of -$0.81
ArriVent BioPharma (AVBP) has announced its third-quarter financial results, reporting a GAAP net loss per share of $0.81 on both a basic and diluted basis. This represents a slight improvement compared to the $0.83 loss reported in the same quarter of the previous year. The company also noted an increase in collaboration revenue, which reached $5 million for the quarter, up from zero in the prior-year period. These results reflect the ongoing transition and scaling of its collaborative research efforts.
Tickers: $AVBP
Topics: earnings net loss revenue growth
Read the full article at Seeking Alpha
Part of the story Sensei Biotherapeutics Reports Q3 GAAP EPS of -$0.79, Slightly Missing Estimates (8 articles)